CLL3 trial

The CLL3 trial was a clinical study evaluating the effectiveness of adding the drug venetoclax to standard chemoimmunotherapy (FCR: fludarabine, cyclophosphamide, and rituximab) in treating chronic lymphocytic leukemia (CLL). The goal was to see if this combination improved treatment outcomes, such as achieving deeper remissions and longer-lasting responses. Conducted with patients new to therapy, the trial found that combining venetoclax increased the rate of undetectable disease levels, suggesting a more effective treatment approach. Overall, the CLL3 trial helped advance strategies to improve CLL management and patient outcomes.